Richard brings over 20 years of multidisciplinary financial experience to 4D pharma. Prior to joining 4D, Richard worked at Fact3 where he worked with high growth companies developing their profitability, internal controls, processes and strategic direction. He brings Corporate Finance experience from his time at BDO, an international network of public accounting, tax and advisory firms, working with clients raising debt and equity finance, including business restructuring. Clients include Secured Mail (now The Delivery Group) and Metronet UK (now M247), which were both listed in the Sunday Times Fast Track 100 during Richard's tenure, and Aquarius Equity (and their portfolio investments) where he worked with founder Duncan Peyton and Alex Stevenson. Richard has a BSc (Hons) in Accountancy, Finance and Computer Science from Lancaster University and qualified as a Chartered Certified Accountant (FCCA) while working as an auditor at RSM.
Christophe graduated in industrial pharmacy, and he started his industrial career as plant manager for Lallemand Bacteria Division, then occupied various positions in R&D and Marketing in B2B of Pharmaceuticals Ingredients. When presented with the challenge of producing Blautix™ he succeeded where others had previously failed and immediately understood the potential of this microorganism. Now, he is in charge of the pharmaceutical industrial development of all the 4D pipeline with the responsibility of all manufacturing sites.
Lucy is responsible for leading and developing 4D pharma's Human Resources strategy across six countries and two continents, as well as overall HR compliance. She has over a decade of experience in HR Management at R&D-focused companies, including establishing and growing these departments. Lucy has a degree in Law & Management from Robert Gordon University in Aberdeen, UK, and Associate status with the Chartered Institute of Personnel and Development (CIPD).
Glenn brings to 4D a wealth of expertise in BioPharma business development and strategy, with extensive experience particularly in NASDAQ-listed biotech and the field of oncology. Previous accomplishments include securing a $200 million collaboration with Roche while Director Business Development at Metabasis, before its acquisition by Ligand Pharmaceuticals where Glenn then served as Senior Director Business Development & Corporate Strategy, overseeing the partnering strategy of one of the most diverse and well-partnered pipelines in biotech. He then joined CAR-T and gene therapy innovator Poseida Therapeutics as Vice President Business Development. Prior to joining 4D, Glenn was Chief Business Officer of oncology specialist 3T Biosciences.
Antonio was the Chief Executive Officer at Instituto Biomar from 2002, leading a group of fermentation specialist and research scientists in microbiology and natural products chemistry. He received his PhD at Houston’s M.D. Anderson Cancer Centre, conducting post-doctoral work in the Departments of Cell Biology and Molecular Pathology from the same institution. After this, Antonio worked in the Departments of Tumour Immunology, at the Dana-Farber Cancer Institute and then Surgical Research at the Children's Hospital, both associated with Harvard Medical School in Boston. He moved back to Spain in 2001, and worked at the research unit in Hospital de Leon from 2001 to 2002, when he joined Instituto Biomar. After the acquisition of Biomar´s production unit by 4D pharma in April 2016, Antonio took up the position of director at 4D pharma Leon.
Imke Mulder is the Research Director at 4D pharma Research Ltd in Aberdeen, Scotland, where she leads a multidisciplinary research group of 30 scientists. After completing her BSc and MSc in Biology at Wageningen University in the Netherlands, she moved to Aberdeen in 2001 to pursue her PhD studies at the Department of Zoology, working on the effects of dietary components on the gut immune system. Imke then carried out 8 years of post-doctoral work as a Research Fellow in the Gut Immunology Group at the Rowett Institute of Nutrition and Health (RINH) in Aberdeen. This work primarily focussed on interactions between the gut microbiota and the host immune system in different model organisms. Specific projects investigated how microbial composition and diversity influences early-life development of the mucosal immune system, and the cell-specific signalling pathways and effector molecules involved in driving health-promoting interactions of the gut microbiota. Imke moved to 4D pharma Research Ltd in 2014 where she leads the development of the MicroRx platform for the discovery of new live biotherapeutics.
Adrian has an undergraduate degree in Medicinal Chemistry from the University of Warwick. Since graduating, Adrian qualified as a UK and European Patent and Trade Mark Attorney, as well as being awarded Chartered Chemist / Scientist status. Throughout his career, Adrian has advised all types of life sciences companies right through from start-ups to multinational giants on the development and implementation of IP protection and litigation strategies, advising on some of the sector’s most high profile IP disputes. He has held the role of Senior Patent Counsel in Teva’s in-house patent department and has also spent several years as a Partner in both a boutique patent and trade mark attorney firm, and, more recently, at international law firm Pinsent Masons.